ArticleInternational journal of nanomedicine2015
Caenorhabditis elegans as an alternative in vivo model to determine oral uptake, nanotoxicity, and efficacy of melatonin-loaded lipid-core nanocapsules on paraquat damage.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 78 citations in OpenAlex.
- Nanoencapsulated buriti oil: toxicological assessment in Caenorhabditis elegans , simulated digestion and enhanced biological potential.Journal of the science of food and agriculture · 2026Article
- Plant polysaccharide nanoparticles: Preparation, applications, andFood chemistry: X · 2026Review
- Toxicity assessment of imatinib mesylate and a related impurity: in vitro and in vivo approaches.Toxicology research · 2025Article
- Nanomaterials as a Potential Target for Infectious Parasitic Agents.Current drug delivery · 2024Review
- High-throughput transcriptome sequencing reveals the protective role of adenosine receptor-related genes in paraquat-exposedToxicology research · 2023Article
- Review
- Acute Toxicity Evaluation of Phosphatidylcholine Nanoliposomes Containing Nisin inMolecules (Basel, Switzerland) · 2023Article
- AdoR-1 (Adenosine Receptor) Contributes to Protection against Paraquat-Induced Oxidative Stress inOxidative medicine and cellular longevity · 2022Article
- A Review on Conventional and Advanced Methods for Nanotoxicology Evaluation of Engineered Nanomaterials.Molecules (Basel, Switzerland) · 2021Review
- Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications.Molecules (Basel, Switzerland) · 2021Review
- Use of nontarget organism Chironomus sancticaroli to study the toxic effects of nanoatrazine.Ecotoxicology (London, England) · 2021Article
- In vitro and in vivo anti-inflammatory activity and chemical composition of Renealmia petasites Gagnep.Inflammopharmacology · 2021Article
- In Vitro and In Vivo Models for Evaluating the Oral Toxicity of Nanomedicines.Nanomaterials (Basel, Switzerland) · 2020Review
- Hydrogen extends Caenorhabditis elegans longevity by reducing reactive oxygen species.PloS one · 2020Article
- Melatonin-loaded lipid-core nanocapsules protect against lipid peroxidation caused by paraquat through increased SOD expression in Caenorhabditis elegans.BMC pharmacology & toxicology · 2019Article
- Use of nanoparticle concentration as a tool to understand the structural properties of colloids.Scientific reports · 2018Article
- Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core Nanocapsules as a Strategy to Target Alpha(V) Beta(3) Integrin Expressed on Tumor Cells.Nanomaterials (Basel, Switzerland) · 2017Article
- DNA damage in the elderly is associated with 5-MTHF levels: a pro-oxidant activity.Toxicology research · 2017Article
- Toxicity-based toxicokinetic/toxicodynamic assessment of bioaccumulation and nanotoxicity of zerovalent iron nanoparticles inInternational journal of nanomedicine · 2017Article
- Voltammetric determination of melatonin using a graphene-based sensor in pharmaceutical products.International journal of nanomedicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caenorhabditis elegans is an alternative in vivo model that is being successfully used to assess the pharmacological and toxic effects of drugs. The exponential growth of nanotechnology requires the use of alternative in vivo models to assess the toxic effects of theses nanomaterials. The use of polymeric nanocapsules has shown promising results for drug delivery. Moreover, these formulations have not been used in cases of intoxication, such as in treatment of paraquat (PQ) poisoning. Thus, the use of drugs with properties improved by nanotechnology is a promising approach to overcome the toxic effects of PQ. This research aimed to evaluate the absorption of rhodamine B-labeled melatonin (Mel)-loaded lipid-core nanocapsules (LNC) by C. elegans, the application of this model in nanotoxicology, and the protection of Mel-LNC against PQ damage. The formulations were prepared by self-assembly and characterized by particle sizing, zeta potential, drug content, and encapsulation efficiency. The results demonstrated that the formulations had narrow size distributions. Rhodamine B-labeled Mel-LNC were orally absorbed and distributed in the worms. The toxicity assessment of LNC showed a lethal dose 50% near the highest dose tested, indicating low toxicity of the nanocapsules. Moreover, pretreatment with Mel-LNC significantly increased the survival rate, reduced the reactive oxygen species, and maintained the development in C. elegans exposed to PQ compared to those worms that were either untreated or pretreated with free Mel. These results demonstrated for the first time the uptake and distribution of Mel-LNC by a nematode, and indicate that while LNC is not toxic, Mel-LNC prevents the effects of PQ poisoning. Thus, C. elegans may be an interesting alternative model to test the nanocapsules toxicity and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.